<DOC>
	<DOCNO>NCT02104986</DOCNO>
	<brief_summary>The main objective ass benefit-risk ratio risk-adapted strategy treatment extra cranial NSMGCT child adolescent .</brief_summary>
	<brief_title>A Multicenter Study Evaluate Risk-adapted Strategy Treatment Extra Cranial Non Seminomateous Malignant Germ Cell Tumour Children Adolescent</brief_title>
	<detailed_description>Two different situation consider : - NSMGCT patient treat cisplatin-based chemotherapy , objective maintain 2-year progression-free survival rate &gt; 80 % despite limitation number course chemotherapy ( ≤4 ) achievement clinical biological response ( primary endpoint ) ; - child 10 year testicular extragonadal NSMGCT , objective improve overall survival systematically classify patient high-risk group allow dose intensification .</detailed_description>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Extra cranial non seminomateous malignant germ cell tumour ( NSMGCT ) except pure immature teratoma . Age ≤ 18 year . Affiliation social security scheme . Signed informed consent parent Effective contraception study relevant . Previous chemotherapy Contraindications study treatment Patient follow medical surveillance due geographical , social , psychological reason Pregnant breast feeding woman</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>non seminomateous malignant germ cell tumour ( NSMGCT )</keyword>
	<keyword>Dose De-escalation</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>